Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $316.54 million. The enterprise value is $350.08 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 268.26 million shares outstanding. The number of shares has increased by 21.26% in one year.
| Current Share Class | 268.26M |
| Shares Outstanding | 268.26M |
| Shares Change (YoY) | +21.26% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 2.23% |
| Owned by Institutions (%) | 45.50% |
| Float | 262.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.36 |
| Forward PS | 1.52 |
| PB Ratio | 11.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.25 |
| P/OCF Ratio | 5.22 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 28.86, with an EV/FCF ratio of 5.83.
| EV / Earnings | n/a |
| EV / Sales | 1.51 |
| EV / EBITDA | 28.86 |
| EV / EBIT | 32.27 |
| EV / FCF | 5.83 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 7.22.
| Current Ratio | 1.40 |
| Quick Ratio | 1.30 |
| Debt / Equity | 7.22 |
| Debt / EBITDA | 11.53 |
| Debt / FCF | 3.29 |
| Interest Coverage | 0.51 |
Financial Efficiency
Return on equity (ROE) is -78.96% and return on invested capital (ROIC) is 3.05%.
| Return on Equity (ROE) | -78.96% |
| Return on Assets (ROA) | 2.02% |
| Return on Invested Capital (ROIC) | 3.05% |
| Return on Capital Employed (ROCE) | 5.75% |
| Weighted Average Cost of Capital (WACC) | 7.06% |
| Revenue Per Employee | $1.20M |
| Profits Per Employee | -$105,727 |
| Employee Count | 194 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.56 |
Taxes
In the past 12 months, AKBA has paid $1.75 million in taxes.
| Income Tax | 1.75M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.23% in the last 52 weeks. The beta is 0.35, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -51.23% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 2.00 |
| Relative Strength Index (RSI) | 37.05 |
| Average Volume (20 Days) | 3,387,284 |
Short Selling Information
The latest short interest is 27.62 million, so 10.30% of the outstanding shares have been sold short.
| Short Interest | 27.62M |
| Short Previous Month | 27.31M |
| Short % of Shares Out | 10.30% |
| Short % of Float | 10.53% |
| Short Ratio (days to cover) | 12.25 |
Income Statement
In the last 12 months, AKBA had revenue of $232.40 million and -$20.51 million in losses. Loss per share was -$0.08.
| Revenue | 232.40M |
| Gross Profit | 190.43M |
| Operating Income | 10.85M |
| Pretax Income | -18.76M |
| Net Income | -20.51M |
| EBITDA | 12.13M |
| EBIT | 10.85M |
| Loss Per Share | -$0.08 |
Full Income StatementBalance Sheet
The company has $162.64 million in cash and $197.52 million in debt, with a net cash position of -$34.88 million or -$0.13 per share.
| Cash & Cash Equivalents | 162.64M |
| Total Debt | 197.52M |
| Net Cash | -34.88M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 27.38M |
| Book Value Per Share | 0.10 |
| Working Capital | 69.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $60.37 million and capital expenditures -$335,000, giving a free cash flow of $60.04 million.
| Operating Cash Flow | 60.37M |
| Capital Expenditures | -335,000 |
| Depreciation & Amortization | 1.28M |
| Net Borrowing | -4.35M |
| Free Cash Flow | 60.04M |
| FCF Per Share | $0.22 |
Full Cash Flow StatementMargins
Gross margin is 81.94%, with operating and profit margins of 4.67% and -8.83%.
| Gross Margin | 81.94% |
| Operating Margin | 4.67% |
| Pretax Margin | -8.07% |
| Profit Margin | -8.83% |
| EBITDA Margin | 5.22% |
| EBIT Margin | 4.67% |
| FCF Margin | 25.83% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.26% |
| Shareholder Yield | -21.26% |
| Earnings Yield | -6.51% |
| FCF Yield | 19.05% |
Analyst Forecast
The average price target for AKBA is $4.67, which is 295.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 295.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 12.23% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -4.43 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.43 |
| Piotroski F-Score | 5 |
